ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.

Relay Therapeutics presented data for RLY-4008 in cholangiocarcinoma at ESMO • Source: Shutterstock

Relay Therapeutics, Inc. has bolstered its case that more precise targeting of fibroblast growth factor receptor 2 (FGFR2) can overcome the limitations of existing FGFR inhibitors in FGFR2-altered cholangiocarcinoma by sidestepping the off-target toxicities associated those drugs, particularly hyperphosphatemia and diarrhea. While the dataset includes only a small number of patients and the median duration of response remains unreached, there were encouraging signs, including a high response rate.

Relay presented the highly anticipated data at the European Society for Medical Oncology meeting on 11 September for RLY-4008, its...